GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » Current Ratio

Elutia (Elutia) Current Ratio : 0.73 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Elutia Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Elutia's current ratio for the quarter that ended in Dec. 2023 was 0.73.

Elutia has a current ratio of 0.73. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Elutia has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Elutia's Current Ratio or its related term are showing as below:

ELUT' s Current Ratio Range Over the Past 10 Years
Min: 0.73   Med: 1.28   Max: 2.23
Current: 0.73

During the past 6 years, Elutia's highest Current Ratio was 2.23. The lowest was 0.73. And the median was 1.28.

ELUT's Current Ratio is ranked worse than
92.62% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: 2.74 vs ELUT: 0.73

Elutia Current Ratio Historical Data

The historical data trend for Elutia's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia Current Ratio Chart

Elutia Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 1.01 2.23 1.82 1.19 0.73

Elutia Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.05 0.84 0.87 0.73

Competitive Comparison of Elutia's Current Ratio

For the Medical Devices subindustry, Elutia's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elutia's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elutia's Current Ratio distribution charts can be found below:

* The bar in red indicates where Elutia's Current Ratio falls into.



Elutia Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Elutia's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=31.253/43.037
=0.73

Elutia's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=31.253/43.037
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elutia  (NAS:ELUT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Elutia Current Ratio Related Terms

Thank you for viewing the detailed overview of Elutia's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Elutia (Elutia) Business Description

Traded in Other Exchanges
N/A
Address
12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Executives
Elutia Pipe Investment, Lp 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc 10 percent owner 688 PINE STREET, BURLINGTON VT 05401
Thomas Englese officer: Chief Commercial Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman director 452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson officer: Chief Financial Officer C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams officer: Chief Scientific Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck 10 percent owner C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp 10 percent owner 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards officer: GENERAL COUNSEL C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015